Roivant's mosliciguat shows PVR reduction in phase 2 PH-ILD trial
Tweet Send to a Friend
Roivant Sciences (Nasdaq: ROIV) announced positive results from its Phase 2 PHocus clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
